MedTrace Logo

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

NCT03673332 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-01-22

No results posted yet for this study

Summary

The co-primary objectives will be to assess the safety and quality of life under treatment.

Conditions

  • Advanced or Metastatic Melanoma
  • Advanced or Metastatic NSCLC

Interventions

DRUG

immune-checkpoint inhibitors therapies

All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.

Sponsors & Collaborators

  • Société Francophone d'Onco-Gériatrie

    collaborator OTHER

  • Institut Paoli-Calmettes

    lead OTHER

Principal Investigators

  • Renaud Sabatier, MD · Institut Paoli-Calmettes

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-16
Primary Completion
2024-10-29
Completion
2024-10-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673332 on ClinicalTrials.gov